Pharsight

1. List of Lonsurf drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9527833	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)
US10457666	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284	TAIHO ONCOLOGY	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor	Sep, 2029 (6 years from now)
US10456399	TAIHO ONCOLOGY	Method for treating cancer patients with severe renal impairment	Feb, 2037 (14 years from now)
US10960004	TAIHO ONCOLOGY	Method for treating cancer patients with severe renal impairment	Feb, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Feb 22, 2022
Orphan Drug Exclusivity (ODE)	Feb 22, 2026

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy; Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf

Dosage: TABLET;ORAL